These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2015-004195-30||A multi-center, randomized, double-blind, placebo-controlled Phase IIa trial to compare the safety of ABX464 given at a fixed dose to placebo in fully controlled HIV infected patients treated with boo...||2017-08-30||due-trials|
|Listed as ongoing, but also has a completion date||2017-000937-30||A Phase IIa study to evaluate the safety and efficacy of ABX464 50 mg once daily versus Placebo in subjects with Moderate to Severe Active Ulcerative Colitis who have failed or are intolerant to immun...||2018-07-25||bad-data|
|Ongoing||2017-003284-35||A follow-up Phase IIa study to evaluate the long-term safety and efficacy profile of ABX464 given at 50 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.||not-yet-due|
|Ongoing||2018-003558-26||A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with mo...||not-yet-due|
|Ongoing||2018-004677-27||Phase IIa randomized, double blind, placebo controlled, parallel group, multiple dose study on ABX464 in combination with methotrexate (MTX), in patients with moderate to severe active Rheumatoid Arth...||not-yet-due|
|Ongoing||2019-000733-39||A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate to severe Ulcerative Colitis.||not-yet-due|
|Ongoing||2019-001578-27||A follow-up Phase 2a open-label study to evaluate the one-year safety and efficacy profile of ABX464 in patients with moderate to severe active Rheumatoid Arthritis.||not-yet-due|
|Ongoing||2020-001673-75||A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure ...||not-yet-due|